TOKYO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/antibodydrug?src=hash" target="_blank"gt;#antibodydruglt;/agt;–Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche has received notification that the EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Hemlibra®, a treatment for hemophilia A created by Chugai, for routine prophylaxis of bleeding episodes in adults and children with severe hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks. The CHMP has also adopted a posi

Source link